CD8A and neoplasm: These data indicate that, in this tumor context, ICB therapy induces NK cell recruitment and/or promotes their maturation/cytotoxicity in the “wrong” compartment, leading to a decrease in CD8+ T-cell abundance and dampened immune cell infiltration.